Glioma is the most common brain tumor, characterized by several histological and malignancy grade. The majority of gliomas are sporadic, but some familial cases have been reported (<5%). Despite hereditary predisposition to gliomas has been associated to rare inherited cancer syndromes, such as Li-Fraumeni and Turcot's syndromes, neurofibromatosis and tuberous sclerosis, not all familial gliomas can be explained by these syndromes. Most familial gliomas seem to be characterized by cluster of two cases, suggesting the involvment of low penetrance factor risks. Moreover, no sex-linked disorders or SNPs on the X chromosome have been associated with increased glioma risk, except for ATRX gene, whose loss-offunction has been observed in 20 % of adult oligodendrogliomas and in 80 % of grade 2 and 3 astrocytomas. Finally, the risk to inherit tumors such as glioma could also be related to combinations of multiple risk variants: besides GWAS analysis identified many SNPs involved in familial gliomas at 5p15.33 (TERT), 7p11.2 (EGFR), 8q24.21 (CCDC26), 9p21.3 (CDKN2A/CDKN2B), 11q23.3 (PHLDB1) and 20q13.33 (RTEL1), mutatio could be associated with the risk of glioma ns in POT1 gene and rare variants in SPAG9 and RUNDC1 genes could be associated with the risk of glioma.
(Alifieris and Trafalis, 2015) . An inverse association between glioma incidence and allergies, atopic diseases and systemic infections has been reported by multiple groups (Goodenberger and Jenkins, 2012) . FAMILIARITY: Excluding those gliomas known to be due to rare hereditary cancer syndromes such as Turcot's and Li-Fraumeni syndromes as well as neurofibromatosis ( NF1, NF2) or tuberous sclerosis (Melin et al., 2017) , there is evidence that gliomas cluster in families. Most familial gliomas appear to comprise clusters of two cases, suggesting low penetrance and a low risk of developing additional gliomas (Sadetzki et al., 2013) . It is currently thought that approximately 5-10% of patients have a family history of glioma (Lindor et al., 2008 , Robertson et al., 2010 . An increased risk of developing primary brain tumors among first-degree relatives of patients with gliomas has been shown (Robertson et al., 2010) , and there is a greater risk for first-degree relatives of probands with a younger age of onset than for first-degree relatives of probands with later onset (Malmer et al., 2003, Blumenthal and Cannon-Albright, 2008) , as shown in Table 3 . when the glioma in the proband was diagnosed before 2007 all gliomas in the family were included in the prevalent cases column; **Excluding three cases with unknown age at diagnosis; comparison between mean age at diagnosis of incident and prevalent p = 0.003; ***p-value = 0.00009 (total incidents versus prevalent); ****For 92 cases of the 831 verified tumours, tumour histological behavior was unknown, and for 58 cases of the 481 verified tumours from the total incident cases, tumour histological behavior was unknown; *****For grades I-II p-value = 0.3 (total incident versus total prevalent). [Modified from Sadetzki et al., 2013] 
Clinics
Gliomas represent 30% of all brain and central nervous system (CNS) tumors and 80% of all malignant brain tumors. The most common and malignant glioma is glioblastoma multiforme (GBM) (Goodenberger and Jenkins, 2012) . Although there are several histologic types of gliomas, the incidence rates for all sporadic gliomas range from 4.67 to 5.73 per 100,000 persons (Barbagallo et al., 2016) . Gliomas are more common in men than in women and in white rather than in black population (Ostrom et al., 2013) . Anyway, familial glioma cases are similar to sporadic ones in terms of gender distribution, age, morphology and grade as shown in Table 2 (results from Gliogene Consortium https://www.bcm.edu/centers/cancercenter/research/gliogene/) (Sadetzki et al., 2013) .
Neoplastic risk
ENVIRONMENTAL: Some epidemiologic risk factors might lead to development of glioma such as therapeutic ionizing radiation, pesticides, smoking, petroleum refining or production work and employment in synthetic rubber manufacturing (Alifieris and Trafalis, 2015) . An inverse association between glioma incidence and allergies, atopic diseases and systemic infections has been reported by multiple groups (Goodenberger and Jenkins, 2012) . FAMILIARITY: Excluding those gliomas known to be due to rare hereditary cancer syndromes such as Turcot's and Li-Fraumeni syndromes as well as neurofibromatosis ( NF1, NF2) or tuberous sclerosis (Melin et al., 2017) , there is evidence that gliomas cluster in families. Most familial gliomas appear to comprise clusters of two cases, suggesting low penetrance and a low risk of developing additional gliomas (Sadetzki et al., 2013) . It is currently thought that approximately 5-10% of patients have a family history of glioma (Lindor et al., 2008 , Robertson et al., 2010 . An increased risk of developing primary brain tumors among first-degree relatives of patients with gliomas has been shown (Robertson et al., 2010) , and there is a greater risk for first-degree relatives of probands with a younger age of onset than for first-degree relatives of probands with later onset (Malmer et al., 2003, Blumenthal and Cannon-Albright, 2008) , as shown in Table 3 .
Anyway, the third-degree relative risks were not significantly elevated for astrocytoma, GBM or for the two types combined (Blumenthal and Cannon-Albright, 2008) . However, familial aggregation of cancer can indicate a genetic etiology but may also indicate shared familial environmental exposures. Unfortunately, a multifactorial inheritance model could not be clearly rejected (Table 4) (de Andrade  et , Malmer et al., 2001 , Shete et al., 2011 . The variation in inherited risk of glioma could be related to combinations of multiple risk variants.
Here, we reported the most significant variants (SNPs) figured out from GWASs ( Kinnersley et al., 2015 , Kinnersley et al., 2015 , Melin et al., 2017 , Ostrom et al., 2014 . , 2015) . In family A, six individuals had POT1 mutation (NM_015450:p.G95C, HG19:chr7:g.124503667C>A), of whom three developed glioma. In family B, also six individuals had POT1 mutation (NM_015450:p.E450X, HG19:chr7:g.124481048C>A) and two developed glioma. Moreover, they identified, in a third family (C), a third protein-changing mutation (NM_015450:p.D617Efs*8, HG19:chr7:g.124464068TTA>T). In families with POT1 mutations, they reported that the affected members suffered from oligodendroglioma, which is substantially sensitive to irradiation. Anyway, the association between familial glioma and POT1 mutations still needs to be validated. Jalali et al. figured out that MYO19 and KIF18B genes and rare variants in SPAG9 and RUNDC1 are potentially involved in familial gliomas (Jalali et al., 2015) .
MENDELIAN CANCER SYNDROMES:
A heritable genetic contribution to gliomagenesis was initially suggested by the increased incidence of these tumors in families with Mendelian cancer syndromes (Table 7) . Although numerous familial cancer syndromes are associated with increased glioma risk, monogenic Mendelian disorders account for only a small proportion of adult glioma incidence at the population level (Ostrom et al., 2014) . However, germline mutations of PTEN, TP53, CDKN2A p16(INK4A)/p14(ARF), and CDK4 are not common events in familial glioma, but occasionally they may account for a subset of familial glioma cases (Tachibana et al., 2000) . Several syndromes are associated to pediatric To date, no sex-linked disorders have been associated with increased glioma risk, nor has any SNP on the X chromosome been identified as a glioma risk factor in previous genome-wide association studies. However, somatic loss of-function mutations in the X chromosome gene Alpha thalassemia/mental retardation syndrome X-linked (ATRX) have been observed in 20 % of adult oligodendroglioma tumors and in 80 % of grade 2 and 3 astrocytomas (Osorio et al., 2015) .
Treatment
Multimodal therapies including surgical resection, radio-and chemotherapy (Bush et al., 2017) .
Evolution
The lower-grade gliomas can evolve towards highergrade ones.
Prognosis
Except for pilocytic astrocytomas ID: 5773>, the median survival of glioma patients is still poor (12-14 months). The 5-years survival of GBM patients is <10%, with a final mortality rate of close to 100% (Roy et al., 2015) .
Cytogenetics

Note
Here, we reported the most karyotype abnormalities associated with familial gliomas found in literature (Table 8 )
Genes involved and proteins
Note Many SNPs could be associated with the risk of glioma at 5p15.33 ( TERT), 7p11.2 ( EGFR), 8q24.21 ( CCDC26), 9p21.3 (CDKN2A/ CDKN2B), 11q23.3 (PHLDB1) and 20q13.33 (RTEL1), mutations in POT1 gene, MYO19 and KIF18B genes and rare variants in SPAG9 and RUNDC1 genes could be associated with the risk of glioma. PTEN, TP53, CDKN2A, and CDK4 are not common events in familial glioma. 
